HK1040718B - 具氟化17α-烷基鏈的抗孕激素活性類固醇 - Google Patents

具氟化17α-烷基鏈的抗孕激素活性類固醇 Download PDF

Info

Publication number
HK1040718B
HK1040718B HK02102580.0A HK02102580A HK1040718B HK 1040718 B HK1040718 B HK 1040718B HK 02102580 A HK02102580 A HK 02102580A HK 1040718 B HK1040718 B HK 1040718B
Authority
HK
Hong Kong
Prior art keywords
hydroxy
pentafluoroethyl
group
estra
fluoroalkyl
Prior art date
Application number
HK02102580.0A
Other languages
English (en)
Chinese (zh)
Other versions
HK1040718A1 (en
Inventor
W‧士威德
A‧克利夫
U‧克拉
G‧尼夫
K‧华立兹
M‧士尼德
U‧福门
H‧荷布-史达普
K‧華立兹
U‧福門
H‧荷布-史達普
Original Assignee
舍林股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 舍林股份公司 filed Critical 舍林股份公司
Publication of HK1040718A1 publication Critical patent/HK1040718A1/xx
Publication of HK1040718B publication Critical patent/HK1040718B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02102580.0A 1997-02-07 2002-04-08 具氟化17α-烷基鏈的抗孕激素活性類固醇 HK1040718B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19706061.7 1997-02-07
DE19706061A DE19706061A1 (de) 1997-02-07 1997-02-07 Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Publications (2)

Publication Number Publication Date
HK1040718A1 HK1040718A1 (en) 2002-06-21
HK1040718B true HK1040718B (zh) 2005-12-09

Family

ID=7820508

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102580.0A HK1040718B (zh) 1997-02-07 2002-04-08 具氟化17α-烷基鏈的抗孕激素活性類固醇

Country Status (35)

Country Link
US (4) US6316432B1 (enExample)
EP (1) EP0970103B1 (enExample)
JP (1) JP4324249B2 (enExample)
KR (1) KR100511815B1 (enExample)
CN (2) CN1246865A (enExample)
AR (1) AR010887A1 (enExample)
AT (1) ATE216397T1 (enExample)
AU (1) AU742834B2 (enExample)
BG (1) BG63875B1 (enExample)
BR (1) BR9807667A (enExample)
CA (1) CA2280041C (enExample)
CL (1) CL2004001191A1 (enExample)
CZ (1) CZ296328B6 (enExample)
DE (2) DE19706061A1 (enExample)
DK (1) DK0970103T3 (enExample)
EA (1) EA003092B1 (enExample)
EE (1) EE03831B1 (enExample)
ES (1) ES2175673T3 (enExample)
HK (1) HK1040718B (enExample)
HU (1) HUP0000968A3 (enExample)
ID (1) ID22643A (enExample)
IL (1) IL131226A (enExample)
IS (1) IS2190B (enExample)
MY (1) MY118508A (enExample)
NO (1) NO313554B1 (enExample)
NZ (1) NZ336989A (enExample)
PL (1) PL191808B1 (enExample)
PT (1) PT970103E (enExample)
SI (1) SI0970103T1 (enExample)
SK (1) SK283155B6 (enExample)
TR (1) TR199901855T2 (enExample)
TW (1) TW499434B (enExample)
UA (1) UA66783C2 (enExample)
WO (1) WO1998034947A1 (enExample)
ZA (1) ZA98985B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
MXPA03002953A (es) * 2000-10-18 2003-08-07 Schering Ag Inhibicion del factor de crecimiento dependiente de las celulas de tumor.
UY26965A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
HRP20030387A2 (en) * 2000-10-18 2005-04-30 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone dependent diseases
DE10051609A1 (de) * 2000-10-18 2002-05-02 Schering Ag Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
JP2004511523A (ja) * 2000-10-18 2004-04-15 シエーリング　アクチエンゲゼルシャフト 細胞におけるアポトシスの誘発のための抗黄体ホルモンの使用
UY26966A1 (es) * 2000-10-18 2002-06-20 Schering Ag Uso de antiprogestinas para la inducción de apoptosis en una célula
CA2433776A1 (en) * 2001-01-09 2002-09-06 Schering Aktiengesellschaft The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
US20020143000A1 (en) * 2001-01-09 2002-10-03 Christa Hegele-Hartung Use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20030013694A1 (en) * 2001-05-25 2003-01-16 Jens Hoffmann Use and compositions of antiprogestins for treatment of prostate diseases
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
DE10221034A1 (de) * 2002-05-03 2003-11-20 Schering Ag 17alpha-Fluoralkyl-11ß-benzaldoxim-Steroide, Verfahren zu deren Herstellung, diese Steroide enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
JP2005536463A (ja) * 2002-05-03 2005-12-02 シエーリング アクチエンゲゼルシャフト １７α−フルオロアルキル−１１β−ベンズアルドキシムステロイド、それらの製造方法、これらのステロイド類を含有する製剤及び医薬品製造のためのそれらの使用
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
US7593347B2 (en) * 2003-12-29 2009-09-22 Intel Corporation Method and apparatus to exchange channel information
EP1862468A1 (de) 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
US9283234B2 (en) 2006-10-24 2016-03-15 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
WO2008128791A2 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
US20100087402A1 (en) * 2008-09-29 2010-04-08 Vivus, Inc. Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders
DE102009034367A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) * 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) * 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) * 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
SG183924A1 (en) 2010-03-22 2012-10-30 Repros Therapeutics Inc Compositions and methods for non-toxic delivery of antiprogestins
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
US20160296534A1 (en) 2013-04-11 2016-10-13 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
US9096641B2 (en) 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US9603856B2 (en) 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
EP2868321A1 (en) 2013-11-03 2015-05-06 Flamina Holding AG A composition or group of compositions for inhibiting autocrine HCG production in adult human cells
MX2017014844A (es) 2015-05-18 2018-02-19 Bayer Pharma AG Regimen modulador selectivo de los receptores de progesterona (sprm).
EP3214092A1 (en) 2016-03-04 2017-09-06 Bayer Pharma Aktiengesellschaft Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE310541C (enExample) * 1915-12-19 1919-01-30
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
US5064821A (en) * 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5272140A (en) * 1987-01-23 1993-12-21 Akzo N.V. 11-aryl steroid derivatives
DE3723788A1 (de) * 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
JP2785023B2 (ja) * 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
JPH02188599A (ja) * 1988-11-16 1990-07-24 Roussel Uclaf ３―ケト―デルタ―４，９―１９―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
CN1055929C (zh) * 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
SI0970103T1 (en) 2002-10-31
DE19706061A1 (de) 1998-08-13
EP0970103B1 (de) 2002-04-17
CA2280041C (en) 2007-10-23
IS2190B (is) 2007-01-15
SK283155B6 (sk) 2003-03-04
US20020045774A1 (en) 2002-04-18
HUP0000968A3 (en) 2001-03-28
JP4324249B2 (ja) 2009-09-02
US6503895B2 (en) 2003-01-07
CN1202120C (zh) 2005-05-18
MY118508A (en) 2004-11-30
EA003092B1 (ru) 2002-12-26
IL131226A0 (en) 2001-01-28
US20030134834A1 (en) 2003-07-17
CL2004001191A1 (es) 2005-03-28
US6316432B1 (en) 2001-11-13
CZ280599A3 (cs) 2000-01-12
ZA98985B (en) 1999-08-03
ES2175673T3 (es) 2002-11-16
JP2001510479A (ja) 2001-07-31
AR010887A1 (es) 2000-07-12
CA2280041A1 (en) 1998-08-13
US20050080060A1 (en) 2005-04-14
WO1998034947A1 (de) 1998-08-13
BR9807667A (pt) 2000-02-15
NZ336989A (en) 2001-04-27
NO993811D0 (no) 1999-08-06
ID22643A (id) 1999-12-02
TR199901855T2 (xx) 2000-04-21
CN1324802A (zh) 2001-12-05
KR100511815B1 (ko) 2005-09-05
NO313554B1 (no) 2002-10-21
EA199900644A1 (ru) 2000-04-24
CN1246865A (zh) 2000-03-08
IS5147A (is) 1999-08-04
PL191808B1 (pl) 2006-07-31
AU742834B2 (en) 2002-01-10
TW499434B (en) 2002-08-21
PT970103E (pt) 2002-09-30
ATE216397T1 (de) 2002-05-15
EE9900339A (et) 2000-02-15
BG103603A (en) 2000-06-30
HK1040718A1 (en) 2002-06-21
NO993811L (no) 1999-10-04
HUP0000968A2 (hu) 2000-10-28
US6806263B2 (en) 2004-10-19
AU6100598A (en) 1998-08-26
EE03831B1 (et) 2002-08-15
DK0970103T3 (da) 2002-07-22
CZ296328B6 (cs) 2006-02-15
US7148213B2 (en) 2006-12-12
UA66783C2 (en) 2004-06-15
EP0970103A1 (de) 2000-01-12
KR20000070835A (ko) 2000-11-25
SK103899A3 (en) 2000-05-16
BG63875B1 (bg) 2003-04-30
PL334878A1 (en) 2000-03-27
IL131226A (en) 2004-12-15
DE59803856D1 (de) 2002-05-23

Similar Documents

Publication Publication Date Title
HK1040718A1 (en) Antigestagenic steroids with a fluorinated 17a-alkyl chain
CN1026324C (zh) 11β-(4-异丙烯基苯基)-4，9-雌二烯，其制法及含此化合物的药剂
CN1257181C (zh) 雄激素甾类化合物以及制备和使用它们的方法
CN1360589A (zh) 口服活性雄激素
CA2277924A1 (en) 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives
CN1166680C (zh) 新颖的雄激素
CN1185249C (zh) 在11位带有烃取代基的非芳香族雌激素甾族化合物
CN1027270C (zh) 14，17β-桥亚乙基-14β-雌三烯和雌四烯的制备方法和含有它们的药物制剂
CN101061132A (zh) 用于制备17－羟基－6β,7β;15β,16β－双亚甲基－17α－孕甾4－烯－3－酮－21－羧酸γ－内酯的方法和用于该方法的关键中间体
JP3048637B2 (ja) Ｄ−ホモ−（１６−ＥＮ）−１１β−アリール４−エストレン、その製法並びに医薬としてのその使用
CN1039328C (zh) D－高－(16－烯)－11β－芳基－4－雌烯－3－酮类化合物的制备方法
CN1481388A (zh) 具有雄激素-孕激素混合活性的14(15)-不饱和的15-和/或16-取代的雄激素类
MXPA99007057A (es) Esteroides con actividad antigestagena que tienen una cadena fluorada de 17-alfa-alquilo
CN1839146A (zh) 具有雄激素作用的△15－d－高甾化合物

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120209